Fierce Biotech
U.S. industry trade / center
Background
Fierce Biotech traces its roots to FierceMarkets, a B2B email newsletter publisher founded in Washington, D.C. in 2000. Questex, a private-equity-backed B2B media company formed in 2005, acquired FierceMarkets in January 2008, bringing Fierce Biotech and related titles into its portfolio. Questex itself changed private equity hands over the years: MidOcean Partners acquired it from Shamrock Capital in September 2018, and in May 2026 MidOcean signed an agreement to sell Questex to funds managed by Apollo Global Management. Fierce Biotech is one of several sister brands under the Questex 'Fierce Life Sciences' umbrella, alongside Fierce Pharma and Fierce Healthcare. The publication has shifted over time from newsletter-style aggregation toward longer enterprise reporting, including clinical trial analysis, M&A coverage, and regulatory tracking. Media Bias/Fact Check rates it 'Least Biased' with 'High' factual reporting, consistent with its trade-press orientation of serving industry readers rather than shaping political opinion. Its coverage of the second Trump term has focused on the practical consequences of FDA staffing cuts and NIH grant freezes for drug development, with no notable editorial advocacy for or against administration policy.
Sources
- About Us | Fierce Biotech
- Questex – Wikipedia
- MidOcean Partners Acquires Questex
- MidOcean Partners Signs Definitive Agreement to Exit Questex
- Questex Strengthens Life Sciences Portfolio – Acquires The Conference Forum and Versalinx
- Fierce Biotech – Bias and Credibility – Media Bias/Fact Check
- DOGE terminates leases for 30 FDA sites | Fierce Biotech
- RFK Jr. cuts 4,700 FDA and NIH jobs | Fierce Biotech
- Advertise | Fierce Biotech
Profile compiled 2026-09-02; refreshed when ownership, funding, or the administration changes.